164 related articles for article (PubMed ID: 34405542)
1. An open-label, nonrandomized, phase Ib feasibility study of cusatuzumab in patients with nasopharyngeal carcinoma.
De Meulenaere A; Vermassen T; Creytens D; De Keukeleire S; Delahaye T; Deron P; Duprez F; Fung S; Pauwels P; Ferdinande L; Rottey S
Clin Transl Sci; 2021 Nov; 14(6):2300-2313. PubMed ID: 34405542
[TBL] [Abstract][Full Text] [Related]
2. Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents.
Riether C; Pabst T; Höpner S; Bacher U; Hinterbrandner M; Banz Y; Müller R; Manz MG; Gharib WH; Francisco D; Bruggmann R; van Rompaey L; Moshir M; Delahaye T; Gandini D; Erzeel E; Hultberg A; Fung S; de Haard H; Leupin N; Ochsenbein AF
Nat Med; 2020 Sep; 26(9):1459-1467. PubMed ID: 32601337
[TBL] [Abstract][Full Text] [Related]
3. Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma.
Leupin N; Zinzani PL; Morschhauser F; Dalle S; Maerevoet M; Michot JM; Ribrag V; Offner F; Beylot-Barry M; Moins-Teisserenc H; Zwaenepoel K; de Winne K; Battistella M; Hultberg A; Gandini D; Moshir M; Jacobs J; Delahaye T; Khan A; Zabrocki P; Silence K; van Rompaey L; Borg C; Motta G; Melle F; Calleri A; Pauwels P; de Haard H; Pileri S; Bagot M
Cancer; 2022 Mar; 128(5):1004-1014. PubMed ID: 34726773
[TBL] [Abstract][Full Text] [Related]
4. Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.
Pabst T; Vey N; Adès L; Bacher U; Bargetzi M; Fung S; Gaidano G; Gandini D; Hultberg A; Johnson A; Ma X; Müller R; Nottage K; Papayannidis C; Recher C; Riether C; Shah P; Tryon J; Xiu L; Ochsenbein AF
Haematologica; 2023 Jul; 108(7):1793-1802. PubMed ID: 36779592
[TBL] [Abstract][Full Text] [Related]
5. Cusatuzumab plus azacitidine in Japanese patients with newly diagnosed acute myeloid leukemia ineligible for intensive treatment.
Ikezoe T; Usuki K; Aida K; Hatayama T; Shirahase T; Yamauchi T
Cancer Sci; 2023 Mar; 114(3):1037-1044. PubMed ID: 36394119
[TBL] [Abstract][Full Text] [Related]
6. The novel high-affinity humanized antibody IMM40H targets CD70, eliminates tumors via Fc-mediated effector functions, and interrupts CD70/CD27 signaling.
Li S; Chen D; Guo H; Liu D; Yang C; Zhang R; Wang T; Zhang F; Bai X; Yang Y; Sun N; Zhang W; Zhang L; Zhao G; Peng L; Tu X; Tian W
Front Oncol; 2023; 13():1240061. PubMed ID: 37849799
[TBL] [Abstract][Full Text] [Related]
7. Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study.
Chen Q; Tang L; Liu N; Han F; Guo L; Guo S; Wang J; Liu H; Ye Y; Zhang L; Liu L; Wang P; Li Y; He Q; Yang X; Tang Q; Li Y; Liang Y; Sun X; Xie C; Mo Y; Guo Y; Sun R; Mo H; Cao K; Guo X; Zeng M; Mai H; Ma J
Cancer Commun (Lond); 2018 Nov; 38(1):66. PubMed ID: 30382933
[TBL] [Abstract][Full Text] [Related]
8. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.
Hsu C; Lee SH; Ejadi S; Even C; Cohen RB; Le Tourneau C; Mehnert JM; Algazi A; van Brummelen EMJ; Saraf S; Thanigaimani P; Cheng JD; Hansen AR
J Clin Oncol; 2017 Dec; 35(36):4050-4056. PubMed ID: 28837405
[TBL] [Abstract][Full Text] [Related]
9. A Phase I/II Open-Label Study of Nivolumab in Previously Treated Advanced or Recurrent Nasopharyngeal Carcinoma and Other Solid Tumors.
Ma Y; Fang W; Zhang Y; Yang Y; Hong S; Zhao Y; Tendolkar A; Chen L; Xu D; Sheng J; Zhao H; Zhang L
Oncologist; 2019 Jul; 24(7):891-e431. PubMed ID: 31048330
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation?
Masterson L; Howard J; Gonzalez-Cruz J; Jackson C; Barnett C; Overton L; Liu H; Ladwa R; Simpson F; McGrath M; Wallwork B; Jones T; Ottensmeier C; Chua MLK; Perry C; Khanna R; Panizza B; Porceddu S; Lechner M
Int J Cancer; 2020 Apr; 146(8):2305-2314. PubMed ID: 31950498
[TBL] [Abstract][Full Text] [Related]
11. Administration of nimotuzumab combined with cisplatin plus 5-fluorouracil as induction therapy improves treatment response and tolerance in patients with locally advanced nasopharyngeal carcinoma receiving concurrent radiochemotherapy: a multicenter randomized controlled study.
Lu Y; Chen D; Liang J; Gao J; Luo Z; Wang R; Liu W; Huang C; Ning X; Liu M; Huang H
BMC Cancer; 2019 Dec; 19(1):1262. PubMed ID: 31888551
[TBL] [Abstract][Full Text] [Related]
12. NPC-0501 trial on the value of changing chemoradiotherapy sequence, replacing 5-fluorouracil with capecitabine, and altering fractionation for patients with advanced nasopharyngeal carcinoma.
Lee AWM; Ngan RKC; Ng WT; Tung SY; Cheng AAC; Kwong DLW; Lu TX; Chan ATC; Sze HCK; Yiu HHY; Wong FCS; Yuen KT; Chappell R; Choi HCW
Cancer; 2020 Aug; 126(16):3674-3688. PubMed ID: 32497261
[TBL] [Abstract][Full Text] [Related]
13. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
[TBL] [Abstract][Full Text] [Related]
14. Sequential induction chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: the three-year report of a phase II, single center, randomized, non-inferiority trial.
Yang Z; Cai Z; Cai Q; Hong Y; Zhang C; Huang K; Lin Z; Li M
Cancer Med; 2021 Jun; 10(12):3886-3895. PubMed ID: 33955190
[TBL] [Abstract][Full Text] [Related]
15. Anti-EGFR therapies in nasopharyngeal carcinoma.
Chen X; Liang R; Zhu X
Biomed Pharmacother; 2020 Nov; 131():110649. PubMed ID: 32836074
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial.
Cao SM; Yang Q; Guo L; Mai HQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Qiu F; Sun R; Chen QY; Huang PY; Luo DH; Hua YJ; Wu YS; Lv X; Wang L; Xia WX; Tang LQ; Ye YF; Chen MY; Guo X; Hong MH
Eur J Cancer; 2017 Apr; 75():14-23. PubMed ID: 28214653
[TBL] [Abstract][Full Text] [Related]
17. ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade.
Silence K; Dreier T; Moshir M; Ulrichts P; Gabriels SM; Saunders M; Wajant H; Brouckaert P; Huyghe L; Van Hauwermeiren T; Thibault A; De Haard HJ
MAbs; 2014; 6(2):523-32. PubMed ID: 24492296
[TBL] [Abstract][Full Text] [Related]
18. Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies.
Aftimos P; Rolfo C; Rottey S; Offner F; Bron D; Maerevoet M; Soria JC; Moshir M; Dreier T; Van Rompaey L; Michot JM; Silence K; Hultberg A; Gandini D; de Haard H; Ribrag V; Peeters M; Thibault A; Leupin N; Awada A
Clin Cancer Res; 2017 Nov; 23(21):6411-6420. PubMed ID: 28765328
[No Abstract] [Full Text] [Related]
19. A phase II multicenter randomized controlled trial to compare standard chemoradiation with or without recombinant human endostatin injection (Endostar) therapy for the treatment of locally advanced nasopharyngeal carcinoma: Long-term outcomes update.
Li Y; Tian Y; Jin F; Wu W; Long J; Ouyang J; Zhou Y
Curr Probl Cancer; 2020 Feb; 44(1):100492. PubMed ID: 32035692
[TBL] [Abstract][Full Text] [Related]
20. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.
Long GV; Atkinson V; Cebon JS; Jameson MB; Fitzharris BM; McNeil CM; Hill AG; Ribas A; Atkins MB; Thompson JA; Hwu WJ; Hodi FS; Menzies AM; Guminski AD; Kefford R; Kong BY; Tamjid B; Srivastava A; Lomax AJ; Islam M; Shu X; Ebbinghaus S; Ibrahim N; Carlino MS
Lancet Oncol; 2017 Sep; 18(9):1202-1210. PubMed ID: 28729151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
